Archana Deskus
Archana Deskus's purchase track record
Archana Deskus has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 5/8/2023 | EWBC | $44K | +37.1% | +31.7% | +5.5% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Cantor Fitzgerald Lowers EWBC Price Target to $146. Cantor Fitzgerald maintained an Overweight rating on East West Bancorp but reduced its price target to $146. The stock is set to report earnings next week, with Wall Street generally expecting growth in key metrics. While the average analyst target remains near $150, this specific adjustment reflects a more cautious outlook on the bank's near-term performance.
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
BofA reinstates Global Payments coverage with $114 target. Bank of America has restarted coverage on Global Payments, issuing a buy rating and a price target of $114. This move places the stock within a broader wave of analyst actions affecting the payments sector, which also saw updates for FIS and Toast. The new target sits above the current average analyst estimate of $105.34, signaling renewed institutional interest in the company's outlook.
Transaction History
| CTSH | ▲ Buy | Option Exercise | 2,919 | — | 6/3/2026 | View on chart |
| EWBC | ▲ Buy | Grant | 1,156 | $0 | 5/18/2026 | View on chart |
| GPN | ▲ Buy | Grant | 3,179 | $0 | 5/1/2026 | View on chart |
| EWBC | ▼ Sell | Open Market | 1,800 | $226K | 4/30/2026 | View on chart |
| GPN | ▲ Buy | Grant | 1,320 | $115K | 9/24/2025 | View on chart |
| CTSH | ▲ Buy | Option Exercise | 3,417 | — | 6/4/2025 | View on chart |
| EWBC | ▲ Buy | Grant | 1,417 | $0 | 5/20/2025 | View on chart |
| CTSH | ▲ Buy | Option Exercise | 3,582 | — | 6/6/2024 | View on chart |
| EWBC | ▲ Buy | Grant | 1,818 | $0 | 5/28/2024 | View on chart |
| CTSH | ▲ Buy | Option Exercise | 2,834 | — | 6/7/2023 | View on chart |
| EWBC | ▲ Buy | Grant | 2,603 | $0 | 5/24/2023 | View on chart |
| EWBC | ▲ Buy | Open Market | 500 | $22K | 5/9/2023 | View on chart |
| EWBC | ▲ Buy | Open Market | 500 | $22K | 5/8/2023 | View on chart |
| EWBC | ▲ Buy | Grant | 2,006 | $0 | 6/30/2022 | View on chart |
| CTSH | ▲ Buy | Option Exercise | 2,949 | — | 6/1/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Cognizant client win raises investor questions
A recent Yahoo article asks whether recent client wins should prompt action from Cognizant investors. The piece highlights that winning new contracts can boost revenue but does not detail any immediate financial impact. The stock is currently near a long‑standing support level and shows a relatively high RSI, which may influence how the market reacts to such news.
Cognizant client win raises investor questions. A recent Yahoo article asks whether recent client wins should prompt action from Cognizant investors. The piece highlights that winning new contracts can boost revenue but does not detail any immediate financial impact. The stock is currently near a long‑standing support level and shows a relatively high RSI, which may influence how the market reacts to such news.